The phase 1 / 2a study of IONIS - HTTRx was recently completed and showed the therapy to be safe and well - tolerated but also showed it's ability to reduce the level of mutant huntingtin in a dose dependent manner in Huntington's Disease patients. (ehdn.org)
This would essentially show the effect of genetics in a quasi dose dependent manner. (sciencedrivennutrition.com)
Furthermore, androstadienone has been shown to maintain increased levels of salivary cortisol in women [7], activate hypothalamus in a sex [8] and sexual orientation dependent manner [9], [10], and activate brain areas related to social cognition and attention [11]. (journals.plos.org)